Akari Therapeutics (AKTX) Lifted to Buy at ValuEngine

ValuEngine upgraded shares of Akari Therapeutics (NASDAQ:AKTX) from a hold rating to a buy rating in a research report sent to investors on Thursday morning.

NASDAQ AKTX opened at $1.90 on Thursday. Akari Therapeutics has a fifty-two week low of $1.62 and a fifty-two week high of $5.49.

Akari Therapeutics (NASDAQ:AKTX) last released its earnings results on Friday, August 17th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter. Equities analysts anticipate that Akari Therapeutics will post -1.27 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Akari Therapeutics stock. Hikari Power Ltd boosted its holdings in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 32.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 843,849 shares of the biopharmaceutical company’s stock after purchasing an additional 207,506 shares during the period. Hikari Power Ltd owned about 7.16% of Akari Therapeutics worth $1,646,000 at the end of the most recent quarter. 16.79% of the stock is owned by institutional investors.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.

Recommended Story: The Role of a Fiduciary and Individual Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply